This inventor holds 1 USPTO granted patent. Top assignee: Philochem Ag. Active years: 2013.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2013
Title: Christoph Dumelln: Innovator in Albumin Binding Molecules
Introduction
Christoph Dumelln is a notable inventor based in Cambridge, MA (US). He has made significant contributions to the field of pharmacology through his innovative work on albumin binding molecules. His research focuses on enhancing the effectiveness of diagnostic and therapeutic agents.
Latest Patents
Dumelln holds a patent for "Albumin binding molecules and uses thereof." This invention pertains to portable albumin binders that improve the pharmacokinetic properties of various agents. Specifically, it aims to increase the blood circulation time and tissue penetration capacity of these agents, thereby enhancing their therapeutic efficacy.
Career Highlights
Christoph Dumelln is associated with Philochem AG, a company that specializes in developing innovative solutions in the field of pharmaceuticals. His work at Philochem AG has allowed him to explore the potential of albumin binding molecules in various medical applications.
Collaborations
Dumelln collaborates with Dario Neri, a fellow researcher, to advance their shared goals in the field of pharmacology. Their partnership has contributed to the development of groundbreaking technologies that aim to improve patient outcomes.
Conclusion
Christoph Dumelln's work on albumin binding molecules represents a significant advancement in the field of pharmacology. His innovative approach has the potential to transform the way therapeutic agents are delivered and utilized in medical treatments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile